Tag : pembrolizumab

Pharma / Biotech

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.

Newsemia
Related Articles Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J Immunother Cancer. 2020 Nov;8(2): Authors: Atkinson...
Latest News

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–FDA Approves KEYTRUDA Plus Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10) Source...
Latest News

Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer

Newsemia
Harrington, KJ; Bhide, SA; Forster, MD; Good, JS; Gunn, L; Kong, A; Melcher, AA; … Wong, KH; + view all Harrington, KJ; Bhide, SA; Forster,...
Latest News

Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

Newsemia
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven...
Latest News

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

Newsemia
KENILWORTH, N.J., & BRUSSELS–(BUSINESS WIRE)—- $MRK #MRK–Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected,...
Gastroenterology

Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report

Newsemia
Therapy targeting programmed death-1 or programmed death-1 ligand-1 (PD-1/PD-L1) has been developed for various solid malignant tumors, such as melanoma and non-small-cell lung cancer (NSCLC),...
Gastroenterology

Pembrolizumab Gets First-Line Indication for mCRC

Newsemia
(MedPage Today) — WASHINGTON — The FDA approved the PD-1 inhibitor pembrolizumab (Keytruda) as initial treatment of metastatic, mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal...
Pharma / Biotech

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.

Newsemia
Related Articles A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020 Apr 15;131:68-75...
Pharma / Biotech

Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.

Newsemia
Related Articles Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma. Oncology. 2020 Jan 14;:1-6 Authors: Kobayashi K, Suzuki...
Pharma / Biotech

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

Newsemia
Related Articles Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019...
Latest News

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #ESMO19–KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response vs Chemotherapy as Neoadjuvant Therapy in TNBC Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy